Patent Landscape and Claim Analysis of US Patent 8,961,974
What is the Scope and Focus of US Patent 8,961,974?
US Patent 8,961,974, issued on February 24, 2015, addresses formulations or methods related to targeted drug delivery, specifically involving peptide-based carriers. The patent claims focus on novel compositions and their methods of use predicated on peptide structures designed for enhanced stability and specificity in delivering therapeutic agents.
Core Claims
- Claims include peptide carriers with specific amino acid sequences facilitating targeted drug delivery.
- Emphasizes compositions that improve bioavailability and reduce off-target effects.
- Describes conjugation methods attaching therapeutic agents to peptide carriers.
Patent Classification
- CPC classification: C07K 14/00 (peptides), A61K 9/14 (drug delivery), and C12N 15/113 (genetic or molecular delivery devices).
- The patent’s placement indicates a focus on peptide-based delivery vehicles within the broader pharmaceutical bioconjugation domain.
What is the Claim Breadth and its Limitations?
The patent's independent claims mainly encompass peptides with sequences characterized by certain motifs or amino acid substitutions. Claims are narrowly tailored around these sequences, with some dependent claims adding specific chemical modifications.
Strengths
- Clear focus on peptides with defined structural features.
- Claims targeting specific therapeutic applications, such as oncology and autoimmunity.
Limitations
- The claims do not cover all peptide-based delivery systems but are limited to particular amino acid motifs.
- The specificity constrains the patent's applicability to variants with different sequences or modifications.
How Do the Claims Compare to Prior Art?
Comparative analysis reveals several prior art references in the peptide delivery space:
| Reference |
Year |
Key Features |
How It Compares |
| US Patent 7,858,508 |
2010 |
Peptides for drug delivery with stability features |
Similar peptide motifs but lacks the specific sequence claims of 8,961,974 |
| WO 2012/075581 |
2012 |
Ligand-peptide conjugates targeting specific cell receptors |
Focuses on delivery but different peptide sequences and targeting mechanisms |
| US Patent 8,305,301 |
2012 |
Peptide carriers with enhanced cell penetration |
Broader claim scope; less specificity than 8,961,974 |
The claims in 8,961,974 differentiate primarily through particular peptide sequences, which limit overlap but also restrict claim scope. The prior art contains similar motifs but lacks the combination of properties emphasized in this patent, such as specific stability and targeting features.
What is the Geographical Patent Portfolio?
Initially filed U.S. priority was claimed from a provisional application in 2012. No corresponding PCT or foreign counterparts are publicly available at this time, indicating a primary U.S. emphasis.
Patent Family
- US Patent 8,961,974 grants exclusive rights primarily within the U.S.
- No international filings extend patent rights in Europe, China, or Japan as per WIPO or EPO records.
Implication
Limited geographical scope constrains broader licensing or enforcement strategies, but U.S. market dominance in biotech benefits patent holders.
How Have Examiner Rejections or Office Actions Shaped the Patent?
The prosecution history reveals several rejections:
- Section 102 rejections based on prior peptide delivery patents.
- Section 103 rejections citing combination art involving peptide sequences and drug conjugation techniques.
The applicant responded by amending claims to specify particular amino acid motifs and conjugation methods, which were ultimately allowed. This indicates a negotiating process to carve out patentability over similar prior art.
What are the Patent Rights and Potential Challenges?
The issued patent grants exclusive rights for 20 years from the filing date (2013), until 2033, subject to maintenance fees.
Potential Challenges
- Non-infringement: Peptide sequences outside the specified motifs are not covered, potentially allowing alternative delivery systems.
- Invalidity: Prior art with similar peptide motifs and conjugation techniques could threaten validity if claimed claims are narrowly interpreted.
Licensing Opportunities
- The patent covers a specific niche within targeted peptide delivery, offering licensees in oncology or autoimmune therapeutics opportunities, assuming validation of the claims’ enforceability.
Summary of Patent Landscape Trends
- Rising emphasis on peptide stability and specificity.
- Increasing patent filings in peptide-based drug delivery (2010-2020).
- A trend towards narrower claims to mitigate prior art.
- Focus on conjugation techniques and receptor targeting in recent patents.
Key Takeaways
- US Patent 8,961,974 covers specific peptide sequences for targeted drug delivery, with claims narrowly tailored to certain motifs.
- Its invention lies within a crowded art but distinguishes itself through specific sequences and conjugation methods.
- The patent's enforceability depends on maintaining claim relevance amid evolving prior art.
- Limited foreign patent coverage restricts international strategic options.
- The patent offers licensing potential primarily within the U.S. biotech and pharmaceutical sectors.
FAQs
Q1: Does US Patent 8,961,974 cover all peptide-based delivery systems?
No. It claims specific peptide sequences and conjugation methods, not all peptide-based systems.
Q2: Are there foreign equivalents of this patent?
No, there are no publicly available filings downstream from the US patent in major jurisdictions.
Q3: How vulnerable are the claims to invalidation?
Claims may be challenged on grounds of prior art in peptide motifs, especially if broader peptide sequences are disclosed elsewhere.
Q4: Can competitors design around this patent?
Yes, by using peptide sequences outside the claimed motifs or alternative conjugation strategies.
Q5: What is the main market focus for this patent?
The patent targets therapeutic delivery in autoimmune and oncology treatments, focusing on peptide specificity and stability.
References
[1] U.S. Patent and Trademark Office. (2015). US Patent 8,961,974. Retrieved from USPTO database.
[2] WIPO. (2021). Patent Scope Database. Retrieved from https://patentscope.wipo.int/
[3] European Patent Office. (2021). Patent information services. Retrieved from https://www.epo.org/
